Inhibrx Q1 2026 net loss $33.4M; cash $161.7M; ozekibart BLA submitted

Inhibrx Biosciences, Inc.

2026-Q1 EPS reported -$2.15

Net loss $33.4M ($2.15/sh) vs $43.3M ($2.80/sh) YoY; R&D expense $25.2M down from $36.9M.
Cash $161.7M at Mar 31, 2026 vs $124.2M at Dec 31, 2025; $75M loan amendment from Oxford.
BLA submitted to FDA for ozekibart in conventional chondrosarcoma; discuss accelerated pathways for CRC and Ewing sarcoma.
INBRX-106 Phase 2 HNSCC updated interim data in May 2026; PFS results expected Q4 2026.
Debt increased to $175M; other expense $2.5M from higher interest on new $75M principal.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.